Novavax, Inc.
Novavax, Inc. NVAX Peers
See (NVAX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVAX | $7.25 | -0.55% | 1.2B | 2.64 | $2.75 | N/A |
| VRTX | $436.00 | +0.45% | 112B | -113.54 | -$3.84 | N/A |
| REGN | $588.34 | -1.43% | 62.5B | 14.95 | $39.36 | +0.30% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $289.96 | +0.33% | 37.8B | -138.74 | -$2.09 | N/A |
| ARGX | $587.61 | +1.06% | 35.9B | 35.85 | $16.39 | N/A |
| BNTX | $98.68 | -0.39% | 23.7B | -27.34 | -$3.61 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $25.85 | +0.31% | 19.1B | -76.03 | -$0.34 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
NVAX vs VRTX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, VRTX has a market cap of 112B. Regarding current trading prices, NVAX is priced at $7.25, while VRTX trades at $436.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas VRTX's P/E ratio is -113.54. In terms of profitability, NVAX's ROE is -1.16%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, NVAX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs REGN Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, REGN has a market cap of 62.5B. Regarding current trading prices, NVAX is priced at $7.25, while REGN trades at $588.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas REGN's P/E ratio is 14.95. In terms of profitability, NVAX's ROE is -1.16%, compared to REGN's ROE of +0.15%. Regarding short-term risk, NVAX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs SGEN Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NVAX is priced at $7.25, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NVAX's ROE is -1.16%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, NVAX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs ALNY Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ALNY has a market cap of 37.8B. Regarding current trading prices, NVAX is priced at $7.25, while ALNY trades at $289.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ALNY's P/E ratio is -138.74. In terms of profitability, NVAX's ROE is -1.16%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, NVAX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs ARGX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ARGX has a market cap of 35.9B. Regarding current trading prices, NVAX is priced at $7.25, while ARGX trades at $587.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ARGX's P/E ratio is 35.85. In terms of profitability, NVAX's ROE is -1.16%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, NVAX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs BNTX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, BNTX has a market cap of 23.7B. Regarding current trading prices, NVAX is priced at $7.25, while BNTX trades at $98.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas BNTX's P/E ratio is -27.34. In terms of profitability, NVAX's ROE is -1.16%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, NVAX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs BGNE Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NVAX is priced at $7.25, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NVAX's ROE is -1.16%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, NVAX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs SMMT Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, SMMT has a market cap of 19.1B. Regarding current trading prices, NVAX is priced at $7.25, while SMMT trades at $25.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas SMMT's P/E ratio is -76.03. In terms of profitability, NVAX's ROE is -1.16%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, NVAX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs DNA-WT Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NVAX is priced at $7.25, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NVAX's ROE is -1.16%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, NVAX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs RPRX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, RPRX has a market cap of 18.2B. Regarding current trading prices, NVAX is priced at $7.25, while RPRX trades at $32.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas RPRX's P/E ratio is 13.24. In terms of profitability, NVAX's ROE is -1.16%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, NVAX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs UTHR Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, UTHR has a market cap of 13.9B. Regarding current trading prices, NVAX is priced at $7.25, while UTHR trades at $307.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas UTHR's P/E ratio is 12.26. In terms of profitability, NVAX's ROE is -1.16%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, NVAX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs GMAB Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, GMAB has a market cap of 12.8B. Regarding current trading prices, NVAX is priced at $7.25, while GMAB trades at $20.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas GMAB's P/E ratio is 12.24. In terms of profitability, NVAX's ROE is -1.16%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, NVAX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs KRTX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NVAX is priced at $7.25, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NVAX's ROE is -1.16%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, NVAX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs INCY Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, INCY has a market cap of 12.4B. Regarding current trading prices, NVAX is priced at $7.25, while INCY trades at $64.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas INCY's P/E ratio is 321.23. In terms of profitability, NVAX's ROE is -1.16%, compared to INCY's ROE of +0.01%. Regarding short-term risk, NVAX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs EXEL Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, EXEL has a market cap of 11.6B. Regarding current trading prices, NVAX is priced at $7.25, while EXEL trades at $42.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas EXEL's P/E ratio is 19.36. In terms of profitability, NVAX's ROE is -1.16%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, NVAX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs BMRN Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, NVAX is priced at $7.25, while BMRN trades at $57.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas BMRN's P/E ratio is 21.31. In terms of profitability, NVAX's ROE is -1.16%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, NVAX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs MRNA Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, MRNA has a market cap of 10.2B. Regarding current trading prices, NVAX is priced at $7.25, while MRNA trades at $26.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas MRNA's P/E ratio is -3.01. In terms of profitability, NVAX's ROE is -1.16%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, NVAX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs ASND Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ASND has a market cap of 9.8B. Regarding current trading prices, NVAX is priced at $7.25, while ASND trades at $162.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ASND's P/E ratio is -24.62. In terms of profitability, NVAX's ROE is -1.16%, compared to ASND's ROE of +1.91%. Regarding short-term risk, NVAX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs RXDX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NVAX is priced at $7.25, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NVAX's ROE is -1.16%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NVAX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs IMGN Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NVAX is priced at $7.25, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NVAX's ROE is -1.16%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, NVAX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs CORT Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, CORT has a market cap of 8.3B. Regarding current trading prices, NVAX is priced at $7.25, while CORT trades at $78.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas CORT's P/E ratio is 68.43. In terms of profitability, NVAX's ROE is -1.16%, compared to CORT's ROE of +0.20%. Regarding short-term risk, NVAX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs CERE Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NVAX is priced at $7.25, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas CERE's P/E ratio is -16.47. In terms of profitability, NVAX's ROE is -1.16%, compared to CERE's ROE of -0.99%. Regarding short-term risk, NVAX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs ROIVW Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, NVAX is priced at $7.25, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, NVAX's ROE is -1.16%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, NVAX is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs ROIV Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, NVAX is priced at $7.25, while ROIV trades at $10.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ROIV's P/E ratio is -10.87. In terms of profitability, NVAX's ROE is -1.16%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, NVAX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs RVMD Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, RVMD has a market cap of 7.4B. Regarding current trading prices, NVAX is priced at $7.25, while RVMD trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas RVMD's P/E ratio is -9.92. In terms of profitability, NVAX's ROE is -1.16%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, NVAX is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs TECH Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, TECH has a market cap of 7.3B. Regarding current trading prices, NVAX is priced at $7.25, while TECH trades at $46.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas TECH's P/E ratio is 56.36. In terms of profitability, NVAX's ROE is -1.16%, compared to TECH's ROE of +0.06%. Regarding short-term risk, NVAX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs HALO Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, HALO has a market cap of 6.7B. Regarding current trading prices, NVAX is priced at $7.25, while HALO trades at $54.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas HALO's P/E ratio is 14.51. In terms of profitability, NVAX's ROE is -1.16%, compared to HALO's ROE of +1.22%. Regarding short-term risk, NVAX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs JAZZ Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, JAZZ has a market cap of 6.7B. Regarding current trading prices, NVAX is priced at $7.25, while JAZZ trades at $108.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas JAZZ's P/E ratio is 14.68. In terms of profitability, NVAX's ROE is -1.16%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, NVAX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs RETA Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NVAX is priced at $7.25, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas RETA's P/E ratio is -66.29. In terms of profitability, NVAX's ROE is -1.16%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NVAX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs BPMC Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, BPMC has a market cap of 6.6B. Regarding current trading prices, NVAX is priced at $7.25, while BPMC trades at $101.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas BPMC's P/E ratio is -40.44. In terms of profitability, NVAX's ROE is -1.16%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, NVAX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs VRNA Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, VRNA has a market cap of 6.4B. Regarding current trading prices, NVAX is priced at $7.25, while VRNA trades at $75.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas VRNA's P/E ratio is -37.53. In terms of profitability, NVAX's ROE is -1.16%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, NVAX is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs BBIO Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, BBIO has a market cap of 6.3B. Regarding current trading prices, NVAX is priced at $7.25, while BBIO trades at $33.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas BBIO's P/E ratio is -9.37. In terms of profitability, NVAX's ROE is -1.16%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, NVAX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs MDGL Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, MDGL has a market cap of 5.9B. Regarding current trading prices, NVAX is priced at $7.25, while MDGL trades at $267.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas MDGL's P/E ratio is -14.99. In terms of profitability, NVAX's ROE is -1.16%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, NVAX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs TLX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, TLX has a market cap of 5.6B. Regarding current trading prices, NVAX is priced at $7.25, while TLX trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas TLX's P/E ratio is 184.44. In terms of profitability, NVAX's ROE is -1.16%, compared to TLX's ROE of +0.14%. Regarding short-term risk, NVAX is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs ABCM Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NVAX is priced at $7.25, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NVAX's ROE is -1.16%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NVAX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs ISEE Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NVAX is priced at $7.25, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NVAX's ROE is -1.16%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NVAX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs TGTX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, TGTX has a market cap of 5.5B. Regarding current trading prices, NVAX is priced at $7.25, while TGTX trades at $34.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas TGTX's P/E ratio is 138.28. In terms of profitability, NVAX's ROE is -1.16%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, NVAX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs NUVL Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, NVAX is priced at $7.25, while NUVL trades at $73.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas NUVL's P/E ratio is -16.63. In terms of profitability, NVAX's ROE is -1.16%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, NVAX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs IONS Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, IONS has a market cap of 5.2B. Regarding current trading prices, NVAX is priced at $7.25, while IONS trades at $32.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas IONS's P/E ratio is -11.03. In terms of profitability, NVAX's ROE is -1.16%, compared to IONS's ROE of -0.00%. Regarding short-term risk, NVAX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs AXSM Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, NVAX is priced at $7.25, while AXSM trades at $105.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas AXSM's P/E ratio is -18.21. In terms of profitability, NVAX's ROE is -1.16%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, NVAX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs ADMA Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ADMA has a market cap of 4.9B. Regarding current trading prices, NVAX is priced at $7.25, while ADMA trades at $20.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ADMA's P/E ratio is 24.31. In terms of profitability, NVAX's ROE is -1.16%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, NVAX is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs ALKS Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, NVAX is priced at $7.25, while ALKS trades at $29.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ALKS's P/E ratio is 13.98. In terms of profitability, NVAX's ROE is -1.16%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, NVAX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs ALPN Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NVAX is priced at $7.25, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NVAX's ROE is -1.16%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, NVAX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs OPT Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NVAX is priced at $7.25, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas OPT's P/E ratio is -1.52. In terms of profitability, NVAX's ROE is -1.16%, compared to OPT's ROE of +2.60%. Regarding short-term risk, NVAX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs PCVX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, NVAX is priced at $7.25, while PCVX trades at $32.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas PCVX's P/E ratio is -8.16. In terms of profitability, NVAX's ROE is -1.16%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, NVAX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs MRTX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NVAX is priced at $7.25, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NVAX's ROE is -1.16%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, NVAX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs RYTM Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, RYTM has a market cap of 4B. Regarding current trading prices, NVAX is priced at $7.25, while RYTM trades at $62.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas RYTM's P/E ratio is -22.27. In terms of profitability, NVAX's ROE is -1.16%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, NVAX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs SLNO Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, SLNO has a market cap of 3.9B. Regarding current trading prices, NVAX is priced at $7.25, while SLNO trades at $76.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas SLNO's P/E ratio is -16.22. In terms of profitability, NVAX's ROE is -1.16%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, NVAX is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs MRUS Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, MRUS has a market cap of 3.8B. Regarding current trading prices, NVAX is priced at $7.25, while MRUS trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas MRUS's P/E ratio is -13.25. In terms of profitability, NVAX's ROE is -1.16%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, NVAX is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs RYZB Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NVAX is priced at $7.25, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NVAX's ROE is -1.16%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NVAX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs CBAY Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NVAX is priced at $7.25, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NVAX's ROE is -1.16%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, NVAX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs SRPT Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, SRPT has a market cap of 3.7B. Regarding current trading prices, NVAX is priced at $7.25, while SRPT trades at $37.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas SRPT's P/E ratio is -14.36. In terms of profitability, NVAX's ROE is -1.16%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, NVAX is more volatile compared to SRPT. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs AKRO Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, AKRO has a market cap of 3.7B. Regarding current trading prices, NVAX is priced at $7.25, while AKRO trades at $46.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas AKRO's P/E ratio is -12.36. In terms of profitability, NVAX's ROE is -1.16%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, NVAX is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs RNA Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, RNA has a market cap of 3.7B. Regarding current trading prices, NVAX is priced at $7.25, while RNA trades at $30.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas RNA's P/E ratio is -10.19. In terms of profitability, NVAX's ROE is -1.16%, compared to RNA's ROE of -0.27%. Regarding short-term risk, NVAX is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs ACAD Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, NVAX is priced at $7.25, while ACAD trades at $21.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ACAD's P/E ratio is 16.04. In terms of profitability, NVAX's ROE is -1.16%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, NVAX is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs CYTK Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, CYTK has a market cap of 3.6B. Regarding current trading prices, NVAX is priced at $7.25, while CYTK trades at $30.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas CYTK's P/E ratio is -5.77. In terms of profitability, NVAX's ROE is -1.16%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, NVAX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs PTCT Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, PTCT has a market cap of 3.6B. Regarding current trading prices, NVAX is priced at $7.25, while PTCT trades at $45.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas PTCT's P/E ratio is 7.06. In terms of profitability, NVAX's ROE is -1.16%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, NVAX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs KRYS Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, KRYS has a market cap of 3.6B. Regarding current trading prices, NVAX is priced at $7.25, while KRYS trades at $125.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas KRYS's P/E ratio is 30.06. In terms of profitability, NVAX's ROE is -1.16%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, NVAX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs ACLX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ACLX has a market cap of 3.5B. Regarding current trading prices, NVAX is priced at $7.25, while ACLX trades at $63.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ACLX's P/E ratio is -21.38. In terms of profitability, NVAX's ROE is -1.16%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, NVAX is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs SWTX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, NVAX is priced at $7.25, while SWTX trades at $46.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas SWTX's P/E ratio is -13.63. In terms of profitability, NVAX's ROE is -1.16%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, NVAX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs RARE Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, RARE has a market cap of 3.4B. Regarding current trading prices, NVAX is priced at $7.25, while RARE trades at $35.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas RARE's P/E ratio is -6.12. In terms of profitability, NVAX's ROE is -1.16%, compared to RARE's ROE of -1.86%. Regarding short-term risk, NVAX is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs CRSP Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, CRSP has a market cap of 3.2B. Regarding current trading prices, NVAX is priced at $7.25, while CRSP trades at $36.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas CRSP's P/E ratio is -8.21. In terms of profitability, NVAX's ROE is -1.16%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, NVAX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs VKTX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, NVAX is priced at $7.25, while VKTX trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas VKTX's P/E ratio is -23.26. In terms of profitability, NVAX's ROE is -1.16%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, NVAX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs CPRX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, NVAX is priced at $7.25, while CPRX trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas CPRX's P/E ratio is 15.60. In terms of profitability, NVAX's ROE is -1.16%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, NVAX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs MTSR Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, MTSR has a market cap of 2.9B. Regarding current trading prices, NVAX is priced at $7.25, while MTSR trades at $27.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas MTSR's P/E ratio is -10.75. In terms of profitability, NVAX's ROE is -1.16%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, NVAX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs MORF Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, NVAX is priced at $7.25, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas MORF's P/E ratio is -14.88. In terms of profitability, NVAX's ROE is -1.16%, compared to MORF's ROE of -0.27%. Regarding short-term risk, NVAX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs MOR Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, NVAX is priced at $7.25, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas MOR's P/E ratio is -12.64. In terms of profitability, NVAX's ROE is -1.16%, compared to MOR's ROE of +7.43%. Regarding short-term risk, NVAX is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs SRRK Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, SRRK has a market cap of 2.8B. Regarding current trading prices, NVAX is priced at $7.25, while SRRK trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas SRRK's P/E ratio is -11.76. In terms of profitability, NVAX's ROE is -1.16%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, NVAX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs PTGX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, PTGX has a market cap of 2.8B. Regarding current trading prices, NVAX is priced at $7.25, while PTGX trades at $45.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas PTGX's P/E ratio is 58.54. In terms of profitability, NVAX's ROE is -1.16%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, NVAX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs CRNX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, NVAX is priced at $7.25, while CRNX trades at $29.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas CRNX's P/E ratio is -7.83. In terms of profitability, NVAX's ROE is -1.16%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, NVAX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs KDNY Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, NVAX is priced at $7.25, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas KDNY's P/E ratio is -12.47. In terms of profitability, NVAX's ROE is -1.16%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, NVAX is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs LEGN Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, LEGN has a market cap of 2.7B. Regarding current trading prices, NVAX is priced at $7.25, while LEGN trades at $28.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas LEGN's P/E ratio is -24.50. In terms of profitability, NVAX's ROE is -1.16%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, NVAX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs MYOV Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, NVAX is priced at $7.25, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas MYOV's P/E ratio is -14.05. In terms of profitability, NVAX's ROE is -1.16%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, NVAX is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs MLTX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, MLTX has a market cap of 2.5B. Regarding current trading prices, NVAX is priced at $7.25, while MLTX trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas MLTX's P/E ratio is -16.93. In terms of profitability, NVAX's ROE is -1.16%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, NVAX is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs IMVT Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, IMVT has a market cap of 2.5B. Regarding current trading prices, NVAX is priced at $7.25, while IMVT trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas IMVT's P/E ratio is -5.52. In terms of profitability, NVAX's ROE is -1.16%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, NVAX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs PRVB Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, NVAX is priced at $7.25, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas PRVB's P/E ratio is -16.43. In terms of profitability, NVAX's ROE is -1.16%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, NVAX is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs APGE Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, APGE has a market cap of 2.4B. Regarding current trading prices, NVAX is priced at $7.25, while APGE trades at $39.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas APGE's P/E ratio is -10.94. In terms of profitability, NVAX's ROE is -1.16%, compared to APGE's ROE of -0.19%. Regarding short-term risk, NVAX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs LBPH Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, NVAX is priced at $7.25, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas LBPH's P/E ratio is -26.66. In terms of profitability, NVAX's ROE is -1.16%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, NVAX is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs AAPG Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, AAPG has a market cap of 2.3B. Regarding current trading prices, NVAX is priced at $7.25, while AAPG trades at $26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas AAPG's P/E ratio is -35.78. In terms of profitability, NVAX's ROE is -1.16%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, NVAX is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs XENE Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, XENE has a market cap of 2.3B. Regarding current trading prices, NVAX is priced at $7.25, while XENE trades at $29.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas XENE's P/E ratio is -9.24. In terms of profitability, NVAX's ROE is -1.16%, compared to XENE's ROE of -0.32%. Regarding short-term risk, NVAX is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs DICE Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, NVAX is priced at $7.25, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas DICE's P/E ratio is -21.91. In terms of profitability, NVAX's ROE is -1.16%, compared to DICE's ROE of +0.56%. Regarding short-term risk, NVAX is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs IBRX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, NVAX is priced at $7.25, while IBRX trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas IBRX's P/E ratio is -4.44. In terms of profitability, NVAX's ROE is -1.16%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, NVAX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs BCRX Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, BCRX has a market cap of 2.2B. Regarding current trading prices, NVAX is priced at $7.25, while BCRX trades at $10.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas BCRX's P/E ratio is -40.73. In terms of profitability, NVAX's ROE is -1.16%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, NVAX is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs APLS Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, APLS has a market cap of 2.2B. Regarding current trading prices, NVAX is priced at $7.25, while APLS trades at $17.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas APLS's P/E ratio is -9.69. In terms of profitability, NVAX's ROE is -1.16%, compared to APLS's ROE of -1.00%. Regarding short-term risk, NVAX is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs MIRM Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, MIRM has a market cap of 2.2B. Regarding current trading prices, NVAX is priced at $7.25, while MIRM trades at $44.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas MIRM's P/E ratio is -27.33. In terms of profitability, NVAX's ROE is -1.16%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, NVAX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs CALT Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, NVAX is priced at $7.25, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas CALT's P/E ratio is -22.73. In terms of profitability, NVAX's ROE is -1.16%, compared to CALT's ROE of -2.10%. Regarding short-term risk, NVAX is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs VCYT Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, NVAX is priced at $7.25, while VCYT trades at $27.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas VCYT's P/E ratio is 64.67. In terms of profitability, NVAX's ROE is -1.16%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, NVAX is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs ARWR Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, ARWR has a market cap of 2.1B. Regarding current trading prices, NVAX is priced at $7.25, while ARWR trades at $15.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas ARWR's P/E ratio is -12.20. In terms of profitability, NVAX's ROE is -1.16%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, NVAX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs VCEL Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, NVAX is priced at $7.25, while VCEL trades at $40.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas VCEL's P/E ratio is 818.40. In terms of profitability, NVAX's ROE is -1.16%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, NVAX is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs BLTE Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, BLTE has a market cap of 2B. Regarding current trading prices, NVAX is priced at $7.25, while BLTE trades at $61.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas BLTE's P/E ratio is -44.85. In terms of profitability, NVAX's ROE is -1.16%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, NVAX is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs NAMS Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, NAMS has a market cap of 2B. Regarding current trading prices, NVAX is priced at $7.25, while NAMS trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas NAMS's P/E ratio is -9.57. In terms of profitability, NVAX's ROE is -1.16%, compared to NAMS's ROE of -0.26%. Regarding short-term risk, NVAX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs NAMSW Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, NAMSW has a market cap of 2B. Regarding current trading prices, NVAX is priced at $7.25, while NAMSW trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas NAMSW's P/E ratio is N/A. In terms of profitability, NVAX's ROE is -1.16%, compared to NAMSW's ROE of -0.26%. Regarding short-term risk, NVAX is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs KNSA Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, NVAX is priced at $7.25, while KNSA trades at $26.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas KNSA's P/E ratio is -112.04. In terms of profitability, NVAX's ROE is -1.16%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, NVAX is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs HRMY Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, HRMY has a market cap of 2B. Regarding current trading prices, NVAX is priced at $7.25, while HRMY trades at $34.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas HRMY's P/E ratio is 13.04. In terms of profitability, NVAX's ROE is -1.16%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, NVAX is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs LGND Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, LGND has a market cap of 2B. Regarding current trading prices, NVAX is priced at $7.25, while LGND trades at $101.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas LGND's P/E ratio is -13.94. In terms of profitability, NVAX's ROE is -1.16%, compared to LGND's ROE of -0.16%. Regarding short-term risk, NVAX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs DNLI Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, DNLI has a market cap of 1.9B. Regarding current trading prices, NVAX is priced at $7.25, while DNLI trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas DNLI's P/E ratio is -5.03. In terms of profitability, NVAX's ROE is -1.16%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, NVAX is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for NVAX.
NVAX vs CGON Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, CGON has a market cap of 1.9B. Regarding current trading prices, NVAX is priced at $7.25, while CGON trades at $25.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas CGON's P/E ratio is -16.96. In terms of profitability, NVAX's ROE is -1.16%, compared to CGON's ROE of -0.17%. Regarding short-term risk, NVAX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs KYMR Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, KYMR has a market cap of 1.9B. Regarding current trading prices, NVAX is priced at $7.25, while KYMR trades at $29.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas KYMR's P/E ratio is -9.48. In terms of profitability, NVAX's ROE is -1.16%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, NVAX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.
NVAX vs FOLD Comparison
NVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVAX stands at 1.2B. In comparison, FOLD has a market cap of 1.9B. Regarding current trading prices, NVAX is priced at $7.25, while FOLD trades at $6.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVAX currently has a P/E ratio of 2.64, whereas FOLD's P/E ratio is -69.11. In terms of profitability, NVAX's ROE is -1.16%, compared to FOLD's ROE of -0.17%. Regarding short-term risk, NVAX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for NVAX.